109. 非典型溶血性尿毒症症候群 Atypical hemolytic uremic syndrome Clinical trials / Disease details
臨床試験数 : 115 / 薬物数 : 37 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 10
Showing 1 to 10 of 115 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-002437-15-HU (EUCTR) | 18/01/2022 | 06/12/2021 | A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolyt ... | A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PH ... | Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.1;Level: LLT;Classification code 10079841;Term: Atypical hemolytic uremic syndrome;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Atypical Hemolytic Uremic Syndrome(aHUS) MedDRA version: 20.1;Level: LLT;Classification code 1007984 ... | Product Name: Crovalimab Product Code: RO7112689/F03-10 INN or Proposed INN: CROVALIMAB Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230 Product Name: Crovalimab Product Code: RO7112689/F03-01 INN or Proposed INN: CROVALIMAB Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230 Product Name: Crovalimab Product Code: RO7112689/F03-10 INN or Proposed INN: CROVALIMAB Other descripti ... | F.Hoffmann-La Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 35 | Phase 3 | United States;Spain;Israel;Italy;France;Hungary;Canada;Belgium;Brazil;Poland;South Africa;China;Japan United States;Spain;Israel;Italy;France;Hungary;Canada;Belgium;Brazil;Poland;South Africa;China;Japa ... | ||
| 2 | NCT04889430 (ClinicalTrials.gov) | January 17, 2022 | 7/5/2021 | Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic SyndromeN ... | A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP ... | Atypical Hemolytic Uremic Syndrome | Drug: Iptacopan | Novartis Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 50 | Phase 3 | Austria;Greece;Japan;Korea, Republic of;Slovenia;Taiwan |
| 3 | JPRN-jRCT2041210086 | 24/12/2021 | 18/10/2021 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pedi ... | A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PH ... | Atypical Hemolytic Uremic Syndrome | RO7112689 (crovalimab): Intravenous and Subcutaneous | Mona D. Shah | NULL | Recruiting | Not applicable | <= 17age old | Both | 35 | Phase 3 | Belgium;Brazil;Canada;France;Hungary;Israel;Italy;China;Poland;South Africa;Spain;United States;Japan Belgium;Brazil;Canada;France;Hungary;Israel;Italy;China;Poland;South Africa;Spain;United States;Japa ... |
| 4 | EUCTR2020-002437-15-IT (EUCTR) | 21/12/2021 | 26/01/2022 | A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolyt ... | A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) - na A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PH ... | Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.1;Level: LLT;Classification code 10079841;Term: Atypical hemolytic uremic syndrome;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Atypical Hemolytic Uremic Syndrome(aHUS) MedDRA version: 20.1;Level: LLT;Classification code 1007984 ... | Product Name: Crovalimab Product Code: [RO7112689/F03-10] INN or Proposed INN: CROVALIMAB Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230 Product Name: Crovalimab Product Code: [RO7112689/F03-01] INN or Proposed INN: CROVALIMAB Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230 Product Name: Crovalimab Product Code: [RO7112689/F03-10] INN or Proposed INN: CROVALIMAB Other descrip ... | F. HOFFMANN - LA ROCHE LTD. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 35 | Phase 3 | United States;Spain;Israel;Italy;France;Hungary;Canada;Belgium;Brazil;Poland;South Africa;China;Japan United States;Spain;Israel;Italy;France;Hungary;Canada;Belgium;Brazil;Poland;South Africa;China;Japa ... | ||
| 5 | EUCTR2020-002437-15-PL (EUCTR) | 08/12/2021 | 04/10/2021 | A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolyt ... | A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PH ... | Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.1;Level: LLT;Classification code 10079841;Term: Atypical hemolytic uremic syndrome;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Atypical Hemolytic Uremic Syndrome(aHUS) MedDRA version: 20.1;Level: LLT;Classification code 1007984 ... | Product Name: Crovalimab Product Code: RO7112689/F03-10 INN or Proposed INN: CROVALIMAB Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230 Product Name: Crovalimab Product Code: RO7112689/F03-01 INN or Proposed INN: CROVALIMAB Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230 Product Name: Crovalimab Product Code: RO7112689/F03-10 INN or Proposed INN: CROVALIMAB Other descripti ... | F.Hoffmann-La Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 35 | Phase 3 | United States;Spain;Israel;Italy;France;Hungary;Canada;Poland;Brazil;Belgium;South Africa;China;Japan United States;Spain;Israel;Italy;France;Hungary;Canada;Poland;Brazil;Belgium;South Africa;China;Japa ... | ||
| 6 | NCT04958265 (ClinicalTrials.gov) | November 16, 2021 | 6/7/2021 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pedi ... | A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS) A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Ph ... | Atypical Hemolytic Uremic Syndrome | Drug: Crovalimab | Hoffmann-La Roche | Chugai Pharmaceutical | Recruiting | N/A | 17 Years | All | 35 | Phase 3 | United States;Canada;China;France;Italy;Japan;Poland;Belgium;Brazil;Hungary;Israel;South Africa;Spain United States;Canada;China;France;Italy;Japan;Poland;Belgium;Brazil;Hungary;Israel;South Africa;Spai ... |
| 7 | EUCTR2020-005186-13-SI (EUCTR) | 05/11/2021 | 14/09/2021 | Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor therapy Efficacy and safety of iptacopan (LNP023) in adult patients with atypical hemolytic uremic syndromen ... | A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP ... | atypical hemolytic uremic syndrome MedDRA version: 20.1;Level: LLT;Classification code 10079841;Term: Atypical hemolytic uremic syndrome;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] atypical hemolytic uremic syndrome MedDRA version: 20.1;Level: LLT;Classification code 10079841;Term ... | Product Name: iptacopan Product Code: LNP023 INN or Proposed INN: iptacopan Other descriptive name: LNP023 HYDROCHLORIDE SALT Product Name: iptacopan Product Code: LNP023 INN or Proposed INN: iptacopan Other descriptive name: LN ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Phase 3 | United States;Czechia;Taiwan;Slovenia;Greece;Austria;Russian Federation;United Kingdom;India;Hungary;Brazil;China;Japan;Korea, Republic of United States;Czechia;Taiwan;Slovenia;Greece;Austria;Russian Federation;United Kingdom;India;Hungary ... | ||
| 8 | EUCTR2020-002437-15-FR (EUCTR) | 28/10/2021 | 02/09/2021 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pedi ... | A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) A PHASE III, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PH ... | Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.1;Level: LLT;Classification code 10079841;Term: Atypical hemolytic uremic syndrome;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Atypical Hemolytic Uremic Syndrome(aHUS) MedDRA version: 20.1;Level: LLT;Classification code 1007984 ... | Product Name: Crovalimab Product Code: RO7112689/F03-10 INN or Proposed INN: CROVALIMAB Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230 Product Name: Crovalimab Product Code: RO7112689/F03-01 INN or Proposed INN: CROVALIMAB Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230 Product Name: Crovalimab Product Code: RO7112689/F03-10 INN or Proposed INN: CROVALIMAB Other descripti ... | F.Hoffmann-La Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 35 | Phase 3 | United States;Spain;Israel;Italy;France;Hungary;Canada;Brazil;Belgium;Poland;South Africa;China;Japan United States;Spain;Israel;Italy;France;Hungary;Canada;Brazil;Belgium;Poland;South Africa;China;Japa ... | ||
| 9 | NCT04861259 (ClinicalTrials.gov) | October 22, 2021 | 23/4/2021 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adul ... | A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS) A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Ph ... | Atypical Hemolytic Uremic Syndrome | Drug: Crovalimab | Hoffmann-La Roche | Chugai Pharmaceutical | Recruiting | 12 Years | N/A | All | 90 | Phase 3 | United States;Belgium;Brazil;Canada;China;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Poland;South Africa;Spain;Turkey;Peru United States;Belgium;Brazil;Canada;China;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Poland;So ... |
| 10 | EUCTR2020-002437-15-ES (EUCTR) | 23/09/2021 | 23/07/2021 | A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS) A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolyt ... | A PHASE III, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB IN ADOLESCENT AND PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) A PHASE III, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALI ... | Atypical Hemolytic Uremic Syndrome (aHUS) MedDRA version: 20.1;Level: LLT;Classification code 10079841;Term: Atypical hemolytic uremic syndrome;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] Atypical Hemolytic Uremic Syndrome(aHUS) MedDRA version: 20.1;Level: LLT;Classification code 1007984 ... | Product Name: Crovalimab Product Code: RO7112689/F03-10 INN or Proposed INN: CROVALIMAB Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230 Product Name: Crovalimab Product Code: RO7112689/F03-01 INN or Proposed INN: CROVALIMAB Other descriptive name: C5 inh MAb, SKY59, RO/CH7092230 Product Name: Crovalimab Product Code: RO7112689/F03-10 INN or Proposed INN: CROVALIMAB Other descripti ... | Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roch ... | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 35 | Phase 3 | United States;Spain;Israel;Italy;France;Hungary;Canada;Brazil;Belgium;Poland;South Africa;China;Japan United States;Spain;Israel;Italy;France;Hungary;Canada;Brazil;Belgium;Poland;South Africa;China;Japa ... |